Oral Etoposide with GM-CSF for Ovarian Cancer
Author Information
Author(s): Baur M, Schernhammer E, Gneist M, Sevelda P, Speiser P, Hudec M, Dittrich Ch
Primary Institution: Applied Cancer Research-Institute for Translational Research VIEnna (ACR-ITR VIEnna), Vienna, Austria
Hypothesis
Chronic oral administration of etoposide may result in significant killing of tumor cells in advanced ovarian cancer patients.
Conclusion
The study defined the maximum tolerated dose of oral etoposide combined with GM-CSF, showing encouraging activity for further investigation.
Supporting Evidence
- 18 patients were treated with varying doses of oral etoposide.
- 7 out of 16 evaluable patients showed a complete or partial response.
- The maximum tolerated dose was determined to be 1000 mg/m2 cycle-1.
Takeaway
This study tested a new way to give a cancer medicine called etoposide to help patients with ovarian cancer feel better and live longer.
Methodology
Patients received oral etoposide for 10 days followed by GM-CSF for 8 days, with dose escalation to find the maximum tolerated dose.
Limitations
The study was nonrandomized and had a small sample size.
Participant Demographics
Median age was 58 years, with a Karnofsky performance status of 80% and 30% having visceral metastases.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website